GBA's "2021 Stock Phantasma"

Advanced Drainage Systems(WMS) has a positive growth outlook as a designer and manufacturer of thermoplastic corrugated pipes and related water management products and drainage solutions. ADS offers materials that tend to be lighter, more durable,e asier to install, and more cost effective than other competing materials. These advantages can help drive key customers to use ADS for their water management needs.

Ok it's not sexy.... We have an interesting BIG theory problem... Water makes power yet some areas are running out of water<---

Many reservoirs are seriously depleted. Lake Oroville, California’s second largest reservoir, helps irrigate a quarter of the nation’s crops and powers 800,000 residents. It is so low that its hydroelectric plant may shut down for the first time ever. California’s more than 1,500 reservoirs are 50% lower than they should be this time of year.

Houston We Have A problem.

Where Hydro works it must be used to power Bitcoins.....<-- Upstate NY and such.... But where hydro is relied upon and the lakes are low... WE NEED A NEW SOLUTION AND FLR HAS THE SOLUTION!!!-- YES the rest of their biz is not so good but they ahave a partnership with a company that can facilitate replacing / augmenting the renewable energy of hydroelectricity with that from other clean sources....

THE COMPANY IS NUSCALE POWER <--- SPAC- A - LISCIOUS . VAN has uncovered little itty bitty nuclear reactors and I agree that's the way to go...

For those not familiar with this private company, NuScale is in the SMR business, standing for “Small Modular [Nuclear] Reactors.”

SO YES TO SMR!!!!! I think ///

small scale reactors promise to deliver fission with a number of advantages:

  • “Point of use” modularity instead of monolithic and undesirable large nukes.
  • The ability to “couple” with other energy sources (wind, solar, etc.) for overall solutions.
  • Improved safety and security again compared to traditionally scaled reactors.
  • Jobs, efficiencies, and economic advantages resulting from component manufacturing.
Various SMR initiatives are underway. Here in the US, the Department of Energy is working with TerraPower (private) that Bill Gates, and Berkshire Hathaway (BRK.A) (BRK.B) via PacifiCorp, fund.<--Booooooo! Partnering with TerraPower is the nuclear energy joint venture between GE and Hitachi.

Alright it's going to be a knock out battle between TerraPower & NuScale <------ Room for both?

Fluor is the majority shareholder in NuScale-! The company is on track to receive a full design certification from the NRC later this year.<-----

“The milestone is the direct result of more than $400 million in funding by the U.S. Department of Energy (DOE) since 2014 to accelerate the development and deployment of SMRs.” - FLR website.

SO VAN BACK TO LOSING TRACK OF IDEAS... YOU HAVE A GOOD ONE LT HERE -- Just it comes with the baggage of the rest of FLR... So we ask ourselves can the infrastructure bill allow us to overlook balance sheets and missed opportunities and let us focus on these small reactors. Imagine taking the pressure off California's water situation and irrigating all those crops. ~stoney
 
Little bit of a heads up... GVA as you all know is our preferred infrastructure play.
And there is an old notion in investing that the longer the base the more the stk moves.

So since March we have been at $38. -> 3/9 = $38.23 EXACTLY WHERE IT IS NOW.. In fact if you look at the chart you will see no dips just an absolute flat line across-- That's rare.

If you were surfing you would get off this wave. But GBA investors are lucky we JUST got in.
& any move from here will be abrupt and powerful.

GVA
Granite Construction Incorporated
$38.42
 
What I want to do is end this thread somehow. And start again with a clear path. I will go through the last two weeks of this thread and pull the relevant ideas and lets start a new one!

The Olympics have been drab though. Originally it sounded like a fun idea lets do an Olympic thread but what of golf stocks? Again and again. I mean these have not been the most exciting Olympics. How could they be with no fans. Why has so much golf been on the air. ZZZzzzzzz. The table tennis has been good, Chinese Dragon guy is fantastic what a player! He has been champion for many years. But China is so good at Ping Pong they wound up playing themselves in the final.

Swimming has been good but boring. I have seen zero boxing, wrestling; very little track and field... they always push that off late it's a mistake when everything else is so blah. Women's beach volley ball... who cares? The outfits can't get any skimpier so the game cannot get any more interesting. I've watched the the men's and women's indoor volleyball a bit. The men's team I've seen a few times they are very very good.

So I'm a bit stuck for a header and I do think it's so important to get these threads off to a good start. I'm a stickler for that.. each of the last two has had a very innocent and funny well meaning start that ends up being entirely compulsion-based and passionate from then on out.
 
Last edited:
Nomination for worst stock of the year- PLTR.

Per latest regulatory filings, its top-level executives and key personnel have collectively sold off $244 million worth of Palantir's Class A shares since 13 May, 2021.- A Holes!
 
vanzandt said:
Turn off the girls' Olympic beach volleyball, and tell me what this means Stoney!!

=======================================

Air T Announces It Will Not Extend the Warrants (AIRTW) to Purchase Alpha Income Preferred Securities (AIRTP) Beyond August 30, 2021
Published
Jun 23, 2021 4:05PM EDT


Warrants (AIRTW) to purchase Alpha Income Preferred Securities (AIRTP) will expire August 30, 2021, as previously announced

DENVER, CO / ACCESSWIRE / June 23, 2021 / Air T, Inc. (NASDAQ:AIRT), announced today that the Warrants ("Warrants") (NASDAQ:AIRTW) to purchase its Alpha Income Preferred (AIP) securities of Air T Funding (NASDAQ:AIRTP) will not be extended.

After two generous extensions, the Warrants will expire as scheduled on August 30, 2021. This leaves only 42 trading days until the Warrants expire. AIRTW holders can buy 8% Trust Preferred securities (NASDAQ: AIRTP) for $24.00. The Trust Preferred securities have closed at or above $25.00 on 24 of the last 30 trading days.

Each Warrant is exercisable for one-tenth of a share of AIP for $2.40. Therefore, each ten (10) Warrants confer upon the holder the right to purchase one (1) full share of AIP for $24.00, representing a 4% discount to the stated value of $25.00 for one share.

The offering of AIP upon exercise of the Warrants is made only by means of a prospectus. Copies of the final prospectus relating to the offering, which is included in Air T's registration statement on Form S-1 (File Nos. 333-228485 and 333-228485-01), and the prospectus supplements dated June 9, 2020, September 2, 2020, January 11, 2021 and May 14, 2021, may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov.

Alternatively, copies of the prospectus and prospectus supplement may be obtained for free from Katrina Philp, Chief of Staff, Air T, Inc., telephone (612) 405-5896, email kphilp@airt.net.



Boy I've tried a few times I don't get it--> stk is $30... I think you highlighted at $28<----- Correction or not?
More...
 
stonedinvestor said:
The danger with SPAC's is thatthey may raise money at any time because PIPE investors are in cheaper.. so as stupid as it sounds CLNN is coming to market....
It will be down pretty good today i bet.

Clene (CLNN)

Clene, a clinical-stage biopharmaceutical company pursuing a unique track in the treatment of neurodegenerative diseases. The company uses nanotechnology to treat bioenergetic failure, and underlying factor in many neurological conditions. The company is developing bioenergetic nanocatalysts, a new class of drugs, to ‘jump start’ neurorepair through an energy-enhancing bioenergetic catalysis. In short, the company’s approach is to improve bio functions at the cellular level, so that the body can repair itself.

Clene has four drug candidates it its pipeline. The leading one, CNN-Au8, is described as a concentrated nanocrystalline gold (Au) suspension that drives critical cellular bioenergetic reactions in the central nervous system. CNN-Au8 is undergoing several concurrent clinical trials, including a Phase 3 trial for amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease) and Phase 2 trials for multiple sclerosis (MS) and Parkinson’s disease. All of these are progressive, chronic, degenerative conditions of the neuromuscular system.

The Phase 3 trial of CNN-Au8 reached the 50% enrollment milestone during Q1. Full enrollment is expected before the end of this year, and topline data is expected to become available during 1H22. Further updates on the company’s various other clinical trial programs are scheduled for later this year.

This company went public in December of last year through a SPAC merger transaction. The merger, with Tottenham Acquisition I Limited brought proceeds of $31.9 million, and saw CLNN shares debut on the NASDAQ on December 31 at $9.01 per share.

Covering CLNN for Cantor Fitzgerald, analyst Charles Duncan set an Overweight (i.e. Buy) rating and a $22 price target that indicates room for ~129% share appreciation from the current $9.63 share price.

“We see the non-specificity of ‘Au8 as a positive for broad applicability to a range of diseases in which oxidative stress and metabolic dysfunction is a key driver of pathophysiology. In addition, although crystalline gold has long been thought to have metabolic activity, it is not until we’ve seen the convergence of deeply scientific knowledge of nanocrystal technology with management capabilities in neurobiology and drug development, that we’ve been compelled to consider the therapeutic potential of gold in the treatment of neurodegenerative diseases," Duncan opined.

The analyst added, "Clene owns patented technology which enables gold nanocrystals to form into specific shapes that are particularly conducive to facilitating nanocatalytic activity and filtering toxic particles from the gold surface to drive differentiated clinical profile, potentially opening the door to broad deployment within medicine.”

In its short time on the public markets, CLNN has attracted 4 analyst reviews – and all are positive, making the analyst consensus a Strong Buy. The stock has an average price target of $22.25, suggesting a 131% one-year upside from current levels.

CLNN-->
Clene Inc. (CLNN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD

$8.68-0.50 (-5.45%)
As of 9:35AM

**Clene files to sell 2.1M shares of common stock for holders 17:04 CLNN
More...


Appears like they have raised money and gotten away with it.
 
stonedinvestor said:

Interesting shift for this co...

Jul. 22, 2021 9:26 AM ET Sintx Technologies, Inc. (SINT) Sintx Technologies, Inc. (SINT)
  • SINTX Technologies(NASDAQ:SINT)enters agreement withB4C, LLC of Dayton, Ohio, to acquire the equipment and technical processes required to make ballisticarmor plates.
  • Separately, the company also entered into a technology license agreement with Precision Ceramics to manufacture a ceramic composite for defense armor applications.
SINT
Sintx Technologies, Inc.
1.67
More...

Great Vol Fri!

Sintx Technologies, Inc. (SINT)-

$1.7000+0.1000 (+6.25%)
At close: July 30 4:00PM EDT
 
You must log in or register to reply here.
Back
Top